EULAR 2013 SIMPONI abstract highlights
2013/06/29 13:05 ÀÔ·Â
Æ®À§ÅÍ·Î ±â»çÀü¼Û ÆäÀ̽ººÏÀ¸·Î ±â»çÀü¼Û
GO-FORWARD 5³â ÀÓ»ó °á°ú
AB0267
 
MTX Åõ¿©¿¡µµ ºÒ±¸ÇÏ°í È°¼ºÀÎ ·ù¸¶Æ¼½º°üÀý¿° ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ °ñ¸®¹«¸¿ÀÇ 5³â È¿°ú¿Í ¾ÈÀü¼º : À§¾à´ëÁ¶, ¹«ÀÛÀ§¹èÁ¤ 3»ó ÀÓ»ó ¿¬±¸ GO-FORWARDÀÇ ÃÖÁ¾ ¿¬±¸ °á°ú
 
E. Keystone 1,*, M. C. Genovese 2, S. Hall 3, P. C. Miranda 4, S.-C. Bae 5, C. Han 6, T. Gathany 6, Y. Zhou 7, S. Xu 7, E. C. Hsia 8
 
1Mount Sinai Hospital, Toronto, Canada, 2Stanford Univ, Palo Alto, United States, 3Monash Univ, Cabrini Med Cent., Malvern, Australia, 4Univ de Chile, Santiago, Chile, 5Hanyang Univ Hospital for Rheumatic Diseases , Seoul, Korea, Republic Of, 6Janssen Global Services, LLC, Malvern, 7Janssen R&D, LLC, Spring House, 8Janssen R&D, LLC/U Penn, Spring House/Philadelphia, United States
 
¸ñÀû: MTX Åõ¿©¿¡µµ ºÒ±¸ÇÏ°í È°¼ºÀÎ ·ù¸¶Æ¼½º°üÀý¿° ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ 3»ó ÀÓ»ó ¿¬±¸(GO-FORWARD)¿¡¼­ÀÇ °ñ¸®¹«¸¿ ÇÇÇÏ Åõ¿© ½ÃÀÇ 5³â°£ÀÇ ¾ÈÀü¼º°ú È¿°ú °á°ú¸¦ º¸±â À§ÇÔ.
 
¹æ¹ý: ȯÀÚµéÀº ¹«ÀÛÀ§·Î À§¾à+MTX±º, °ñ¸®¹«¸¿ 100mg+À§¾à±º, °ñ¸®¹«¸¿ 50mg+MTX±º ¶Ç´Â °ñ¸®¹«¸¿ 100mg+MTX±ºÀ¸·Î ¹èÁ¤¹Þ¾Æ 4ÁÖ¸¶´Ù ½ÃÇè¾àÀ» ÇÇÇÏÁÖ»ç·Î Åõ¿©ÇÏ¿´´Ù. À§¾à+MTX±ºÀº °ñ¸®¹«¸¿+MTX·Î, 16ÁÖÂ÷¿¡ EE(early escape)Çϰųª 24ÁÖÂ÷¿¡ ±³Â÷Åõ¿© µÇ¾ú´Ù. ¸¶Áö¸· ȯÀÚ°¡ 52ÁÖ±îÁö Åõ¿©¸¦ ¸¶Ä£ ÈÄ È¯ÀÚµéÀº ¸Í°ËÀ» Á¾·áÇß°í MTX¿Í corticosteroidÀÇ »ç¿ëÀÌ Á¶Á¤µÉ ¼ö ÀÖ¾ú´Ù. ¶ÇÇÑ ¿¬±¸ÀÚÀÇ ÆÇ´Ü ÇÏ¿¡ 1ȸ °ñ¸®¹«¸¿ Åõ¿©¿ë·®ÀÌ 50mg¿¡¼­ 100mg·Î Áõ·®µÇ°Å³ª 100mg¿¡¼­ 50mgÀ¸·Î °¨·®µÉ ¼ö ÀÖ¾ú´Ù. ¸¶Áö¸· °ñ¸®¹«¸¿ Åõ¿©´Â 252ÁÖ¿¡ ÀÌ·ç¾îÁ³´Ù. ¹«ÀÛÀ§ Ä¡·á±ºº°·Î È¿°ú °üÂû °á°ú(ACR20/50/70, DAS28-CRP, HAQ-DI, ¹æ»ç¼±ÇÐÀû ÁøÇà)´Â 256ÁÖ±îÁö ´©ÀûµÈ ¾ÈÀü¼º °á°ú´Â 268ÁÖ±îÁö °¢°¢ º¸°íµÇ¾ú´Ù.
 
°á°ú: ÃÑ 444¸íÀÇ ·ù¸¶Æ¼½º °üÀý¿° ȯÀÚ Áß 313¸í(71%)ÀÌ 252ÁÖ±îÁö Åõ¿©¸¦ Áö¼ÓÇß°í 131¸íÀÌ Åõ¿©¸¦ Áß´Ü(ÀÌ»ó¹ÝÀÀ:64¸í, È¿°ú ºÎÁ·:25¸í(5.6%), ÀÓ»ó½ÃÇè°èȹ¼­ À§¹Ý: 1¸í, ÃßÀû ½ÇÆÐ: 6¸í, ±âŸ»çÀ¯: 32¸í, »ç¸Á: 3¸í)ÇÏ¿´´Ù. 301¸íÀÌ 268ÁÖ±îÁö ¾ÈÀü¼º °üÂû ÃßÀûÀ» ¸¶ÃÆ´Ù. 256ÁÖÂ÷¿¡ 89.5%ÀÇ È¯ÀÚ°¡ DAS28-CRP EULAR response¸¦, 76%ÀÇ È¯ÀÚ°¡ ACR20À» º¸¿´À¸¸ç HAQ-DI(¡Ã0.25)°³¼±ÀÌ ÀÖ¾ú´ø ȯÀÚ´Â 68.5%¿¡ À̸£·¶´Ù. 5³â°£ Æò±Õ Total vdH-S Á¡¼ö·Î º» ¹æ»ç¼±ÇÐÀû ÁøÇàÀº ±âÃÊ Æò°¡ ½ÃÁ¡ ´ëºñ Àû¾ú°í, °ñ¸®¹«¸¿À¸·Î ¹«ÀÛÀ§¹èÁ¤µÈ ȯÀÚµéÀÇ 54%°¡ ¹æ»ç¼±ÇÐÀû ÁøÇà(radiographic progression)ÀÌ ¾ø¾ú´Ù. È¿°ú °á°ú´Â Ç¥¿¡ ³ªÅ¸³»¾ú´Ù. °¡Àå ÈçÇÑ ÀÌ»ó¹ÝÀÀÀº »ó±âµµ°¨¿°À¸·Î 32.9%¿´°í, ºñÀεο°ÀÌ 17.1%, ±â°üÁö¿° 17.1%, ÁÖ»çºÎÀ§¹ÝÀÀÀº 9.2%¿´´Ù. 268ÁÖ±îÁö 39.6%ÀÇ È¯ÀÚ¿¡¼­ Áß´ëÇÑ ÀÌ»ó¹ÝÀÀÀÌ ¹ßÇöµÇ¾ú°í 14.1%ÀÇ È¯ÀÚ°¡ ÀÌ»ó¹ÝÀÀÀ¸·Î ÀÎÇÏ¿© Åõ¿©¸¦ Áß´ÜÇÏ¿´´Ù. Áß´ëÇÑ °¨¿°, ¾Ç¼ºÁ¾¾ç, »ç¸ÁÀº °¢°¢ 11.5%, 6.2%, 1.8%¿´´Ù. »ùÇÃÀÌ À¯È¿ÇÑ 429¸í Áß 7.7%(33¸í)¿¡¼­ antibody-to-golimumab¿¡ ¾ç¼ºÀ» º¸¿´´Ù.
 
°á·Ð: ½ÉÆÛ´Ï´Â Åõ¾àÀ¯ÁöÀ²ÀÌ 70.5%·Î ³ô¾Ò°í, °ñ¸®¹«¸¿+MTX Åõ¿©´Â ·ù¸¶Æ¼½º°üÀý¿°ÀÇ Áõ»ó/¡ÈÄ¿Í ½ÅüÀû ±â´ÉÀÇ Çâ»óÀ» Àå±â°£ À¯ÁöÇÏ¿´´Ù. ¹æ»ç¼±ÇÐÀû ÁøÇàÀº 5³â°£ vdH-S Á¡¼ö(Áß°£°ª)»ó ÀûÀº º¯È­¸¸À» º¸À̸ç Á¶ÀýµÇ´Â °ÍÀ¸·Î °üÂûµÇ¾ú´Ù. °ñ¸®¹«¸¿ÀÇ Àå±â ¾ÈÀü¼ºÀº ´Ù¸¥ Ç×-TNF Á¦Á¦µé°ú À¯»çÇÏ¿´´Ù.
 
Disclosure of Interest: E. Keystone Grant/research support from: Janssen R&D, LLC, M. Genovese Grant/research support from: Janssen R&D, LLC, S. Hall Grant/research support from: Janssen R&D, LLC, P. Miranda Grant/research support from: Janssen R&D, LLC, S.-C. Bae Grant/research support from: Janssen R&D, LLC, C. Han
Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, T.
Gathany Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services,
LLC, Y. Zhou Shareholder of: Johnson & Johnson, Employee of: Janssen R&D, LLC, S. Xu
Shareholder of: Johnson & Johnson, Employee of: Janssen R&D, LLC, E. Hsia
Shareholder of: Johnson & Johnson, Employee of: Janssen R&D, LLC
 
FRI0178
GO-BEFORE 5³â ÀÓ»ó°á°ú
¸ÞÅäÆ®·º¼¼ÀÌÆ®¸¦ Åõ¿©ÇÑ ÀûÀÌ ¾ø´Â ·ù¸¶Æ¼½º °üÀý¿° ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ °ñ¸®¹«¸¿ÀÇ 5³â ¾ÈÀü¼º°ú È¿°ú: À§¾à´ëÁ¶, ¹«ÀÛÀ§¹èÁ¤ 3»ó ÀÓ»ó ¿¬±¸ GO-BEFOREÀÇ ÃÖÁ¾ ¿¬±¸ °á°ú
 
P. Emery 1,*, R. M. Fleischmann 2, I. Strusberg 3, P. Durez 4, P. Nash 5, E. Amante 6, M.
Churchill 8, W. Park 7, B. Pons-Estel 9, C. Han 10, T. Gathany 10, Y. Zhou 11, S. Xu 11, E. C.
Hsia 12
 
1Univ of Leeds, Leeds, United Kingdom, 2Univ of Texas, SWMC, Dallas, United States,
3Inst Reumatologico Strusberg, Cordoba, Argentina, 4Univ Catholique de Louvain,
Brussels, Belgium, 5Univ of Queensland, Brisbane, Australia, 6Univ of the Philippines,
Manila, Philippines, 7INHA Univ Hospital, Incheon, Korea, Republic Of, 8Arthritis Cent of
Nebraska, Lincoln, United States, 9Inst Cardiovascular de Rosario, Santa Fe, Argentina,
10Janssen Global Services, LLC, Malvern, 11Janssen R&D, LLC, Spring House, 12Janssen
R&D, LLC/U Penn, Spring House/Philadelphia, United States
 
¸ñÀû: MTX¸¦ Åõ¿©ÇÑ ÀûÀÌ ¾ø´Â ·ù¸¶Æ¼½º °üÀý¿° ȯÀÚ¿¡¼­ÀÇ °ñ¸®¹«¸¿+/-MTX¸¦ Æò°¡ÇÑ 3»ó ÀÓ»ó ¿¬±¸(GO-BEFORE)ÀÇ ÃÖÁ¾ 5³âÀÇ ¾ÈÀü¼º°ú È¿°ú¸¦ º¸°í.
 
¹æ¹ý: ÇÇÇèÀÚµéÀº À§¾à+MTX, °ñ¸®¹«¸¿100mg+À§¾à, °ñ¸®¹«¸¿50mg+MTX, °ñ¸®¹«¸¿ 100mg+MTX±ºÀ¸·Î ¹«ÀÛÀ§¹èÁ¤µÇ¾î 4ÁÖ¸¶´Ù ½ÃÇè¾àÀ» Åõ¿©ÇÏ¿´´Ù. À§¾à+MTX±ºÀº 28ÁÖÂ÷¿¡ °ñ¸®¹«¸¿+MTXÀ¸·Î ±³Â÷ Åõ¿©(blinded early escape)Çϰųª, 52ÁÖÂ÷¿¡ °ñ¸®¹«¸¿+MTXÀ¸·Î ±³Â÷ Åõ¿©(¾ÐÅë/ºÎÁ¾ °üÀýÀÌ Çϳª ÀÌ»ó ÀÖ´Â °æ¿ì)ÇÏ¿´´Ù. ȯÀÚµéÀº 52ÁÖÂ÷±îÁö Ä¡·á¸¦ Áö¼ÓÇÏ¿´´Ù. ¸¶Áö¸· 52ÁÖÂ÷ ½ÃÇèÀÌ Á¾·áµÇ°í ¸Í°ËÀ» ÇØÁ¦ÇÑ ÈÄ, À§¾à+MTX ±ºÀÇ È¯ÀÚµéÀº °ñ¸®¹«¸¿50mg+MTX·Î ±³Ã¼ÇÏ¿´°í, MTX ±×¸®°í corticosteroid´Â Á¶Á¤µÇ¾ú´Ù. ¿¬±¸ÀÚÀÇ ÆÇ´Ü ÇÏ¿¡ 1ȸ °ñ¸®¹«¸¿ Åõ¿©¿ë·®À» º¯°æ(50¿¡¼­100 ¶Ç´Â 100¿¡¼­ 50)ÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù. ¸¶Áö¸· °ñ¸®¹«¸¿ÀÇ Åõ¿©´Â 252ÁÖ¿¡ ÀÌ·ïÁ³½À´Ï´Ù. ¹«ÀÛÀ§ Ä¡·á±ºº°·Î È¿°ú °üÂû °á°ú (ACR20/50/70, DAS28-CRP, HAQ-DI, ¹æ»ç¼±ÇÐÀû ÁøÇà)´Â 256ÁÖ±îÁö, ´©ÀûµÈ ¾ÈÀü¼º °á°ú´Â 268ÁÖ±îÁö °¢°¢ º¸°íµÇ¾ú½À´Ï´Ù.
 
°á°ú: 637¸íÀÇ ¹«ÀÛÀ§ ¹èÁ¤µÈ ȯÀÚ Áß 3¸íÀº ½ÃÇè¾àÀ» Åõ¿©¹ÞÁö ¾Ê¾Ò½À´Ï´Ù. 419¸íÀº 252ÁÖ±îÁö Ä¡·á¸¦ Áö¼ÓÇÏ¿´°í 215¸íÀº Ä¡·á¸¦ Áß´Ü(111¸í: ÀÌ»ó¹ÝÀÀ, 23¸í: È¿°ú ºÎÁ·(3.6%), 20¸í: ÃßÀû Á¶»ç ½ÇÆÐ, 53¸í: ±âŸ ÀÌÀ¯, 8¸í: »ç¸Á)ÇÏ¿´½À´Ï´Ù. 402¸íÀº 268ÁÖ±îÁö ¾ÈÀü¼º °üÂû ÃßÀûÀ» ¿Ï·áÇÏ¿´½À´Ï´Ù. È¿°ú¿¡ °üÇÑ °á°ú´Â Ç¥¿¡ ³ªÅ¸³»¾ú½À´Ï´Ù. 256ÁÖÂ÷¿¡ 84.3%ÀÇ È¯ÀÚ°¡ ACR20¸¦, 93.9%ÀÇ È¯ÀÚ´Â DAS28-CRP EULAR response¸¦ ¸¸Á·½ÃÄ×°í 80.6%ÀÇ È¯ÀÚ´Â 0.25 ÀÌ»óÀÇ HAQ-DI °³¼±ÀÌ ÀÖ¾ú½À´Ï´Ù. ±âÃÊ Æò°¡ ½ÃÁ¡ ´ëºñ ÃÑ vdH-S Á¡¼ö º¯È­´Â Àû¾ú°í °ñ¸®¹«¸¿+MTX ±ºÀÇ 64%´Â ¹æ»ç¼±ÇÐÀû ÁøÇàÀÌ ¾ø¾ú½À´Ï´Ù. °¡Àå ÈçÇÑ ÀÌ»ó¹ÝÀÀÀº »ó±âµµ°¨¿°(29.4%), ±¸¿ª(19.6%), ±â°üÁö¿°(16.6%)°ú ¾Ë¶ó´Ñ ¾Æ¹Ì³ëÀüÀÌÈ¿¼Ò(ALT) Áõ°¡¿´°í, 11.9%¿¡¼­ ÁÖ»çºÎÀ§ ¹ÝÀÀÀÌ ÀÖ¾ú½À´Ï´Ù. 268ÁÖ µ¿¾È 204/616(33.1%)ÀÇ È¯Àڵ鿡¼­ Áß´ëÇÑ ÀÌ»ó¹ÝÀÀÀÌ ³ªÅ¸³µÀ¸¸ç, 17.5%´Â ÀÌ»ó¹ÝÀÀÀ¸·Î ÀÎÇØ ÀÓ»óÀ» Áß´ÜÇÏ¿´½À´Ï´Ù. ½É°¢ÇÑ °¨¿°, ¾Ç¼ºÁ¾¾ç, »ç¸ÁÀº °¢°¢ 12.2%, 3.4%, 1.9%¿´´Ù. »ùÇÃÀÌ À¯È¿ÇÑ 595¸í Áß, 58(9.7%)¸í¿¡¼­ °ñ¸®¹«¸¿¿¡ ´ëÇÑ Ç×ü°¡ ¾ç¼ºÀ̾ú½À´Ï´Ù.
 
°á·Ð: 5³â°£ ¾à¹°À¯ÁöÀ²Àº 66.1%·Î ³ô¾Ò½À´Ï´Ù. °ñ¸®¹«¸¿+MTX ¿ä¹ýÀº ·ù¸¶Æ¼½º°üÀý¿°ÀÇ Áõ»ó/¡¿Í ½ÅüÀû ±â´ÉÀÇ °³¼±À» Àå±â°£ À¯ÁöÇÏ¿´°í, Àå±âÀû ±¸Á¶¼Õ»óÁøÇàÀ» ¾ïÁ¦ÇÏ¿´½À´Ï´Ù. MTX¸¦ Åõ¿©ÇÏÁö ¾Ê¾Ò´ø ·ù¸¶Æ¼½º°üÀý¿° ȯÀڵ鿡¼­ 5³â°£ »õ·Î¿î Ưº°ÇÑ ¾ÈÀü¼º ¡ÈÄ´Â °üÂûµÇÁö ¾Ê¾Ò½À´Ï´Ù.
 
Disclosure of Interest: P. Emery Grant/research support from: Janssen R&D, LLC, R.
Fleischmann Grant/research support from: Janssen R&D, LLC, I. Strusberg
Grant/research support from: Janssen R&D, LLC, P. Durez Grant/research support
from: Janssen R&D, LLC, P. Nash Grant/research support from: Janssen R&D, LLC, E.
Amante Grant/research support from: Janssen R&D, LLC, M. Churchill Grant/research
support from: Janssen R&D, LLC, W. Park Grant/research support from: Janssen R&D,
LLC, B. Pons-Estel Grant/research support from: Janssen R&D, LLC, C. Han Shareholder
of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, T. Gathany
Shareholder of: Johnson & Johnson, Employee of: Janssen Global Services, LLC, Y. Zhou
Shareholder of: Johnson & Johnson, Employee of: Janssen R&D, LLC, S. Xu Shareholder
of: Johnson & Johnson, Employee of: Janssen R&D, LLC, E. Hsia Shareholder of:
Johnson & Johnson, Employee of: Janssen R&D, LLC
 
THU0202
GO- AFTER 5³â ÀÓ»ó °á°ú
Ç× TNF Á¦Á¦ Åõ¿©¿¡µµ ºÒ±¸ÇÏ°í È°¼ºÀÎ ·ù¸¶Æ¼½º°üÀý¿° ȯÀÚ¿¡¼­ °ñ¸®¹«¸¿ÀÇ 5³â ¾ÈÀü¼º°ú È¿°ú: À§¾à´ëÁ¶, ¹«ÀÛÀ§¹èÁ¤ 3»ó ÀÓ»ó ¿¬±¸ GO-AFTERÀÇ ÃÖÁ¾ ¿¬±¸ °á°ú FINAL STUDY RESULTS OF THE PHASE 3, RANDOMIZED, PLACEBO-CONTROLLED GO-AFTER TRIAL
 
J. S. Smolen 1,*, J. Kay 2, R. Landewe 3, E. L. Matteson 4, N. Gaylis 5, J. Wollenhaupt 6, F. T. Murphy 7, C. Han 8, T. Gathany 8, S. Xu 9, Y. Zhou 9, E. C. Hsia 10, M. K. Doyle 9
 
1Medical Univ of Vienna; Hietzing Hospital, Vienna, Austria, 2UMass Memorial Medical Center, Worcester, United States, 3Univ of Amsterdam; Atrium Medical Center, Heerlen, Netherlands, 4Mayo Clinic College of Med, Rochester, 5Arthritis & Rheumatic Disease Specialties, Aventura, United States, 6Schoen Klinik Hamburg Eilbek, Hamburg, Germany, 7Altoona Center for Clinical Research, Altoona, 8Janssen Global Services, LLC, Malvern, 9Janssen R&D, LLC, Spring House, 10Janssen R&D, LLC/U Penn, Spring House/Philadelphia, United States
 
¹è°æ:  GO-AFTER was the first multicenter, randomized, placebo (PBO)-controlled trial of the safety/efficacy of an anti-TNF-a agent, GLM, in pts with active RA despite prior anti-TNF-a therapy.
 
¸ñÀû: 5³â µ¿¾ÈÀÇ ¾ÈÀü¼º/È¿°ú °á°ú º¸°í.
 
¹æ¹ý: ȯÀÚµéÀº À§¾à±º,, GLM 50mg, or GLM 100mg±ºÀ¸·Î 1:1:1·Î ¹èÁ¤µÇ¾î 4ÁÖ¸¶´Ù ½ÃÇè¾àÀ» Åõ¿©ÇÏ¿´´Ù. 16ÁÖÂ÷¿¡ ºÒÃæºÐÇÑ Ä¡·á ¹ÝÀÀÀ» º¸ÀÌ´Â ÀÌÁß¸Í°Ë early escape µÇ¾ú´Ù. 24ÁÖÂ÷(Àå±â ¿¬Àå ½ÃÀÛ ½ÃÁ¡)¿¡, °è¼Ó À§¾àÀ» Åõ¿©ÇÏ´ø ȯÀÚµéÀº GLM50mgÀ¸·Î ¹Ù²î¾ú°í, ´Ù¸¥ ¸ðµç ȯÀÚµéÀº ÇöÀçÀÇ Ä¡·á¸¦ °è¼ÓÇÏ¿´´Ù. ¸¶Áö¸· ȯÀÚ°¡ 24ÁÖÂ÷ ¹æ¹®À» ¿Ï·áÇÑ ÈÄ, ¸Í°ËÀ» ÇØÁ¦ÇÏ¿´°í, ¿¬±¸ÀÚÀÇ ÆÇ´Ü ÇÏ¿¡ 1ȸ °ñ¸®¹«¸¿ Åõ¿© ¿ë·®ÀÌ 50mg¿¡¼­ 100mg·Î Áõ·®µÇ°Å³ª 100mg¿¡¼­ 50mgÀ¸·Î °¨·®µÉ ¼ö ÀÖ¾ú´Ù. ¹«ÀÛÀ§ ¹èÁ¤µÈ Ä¡·á±ºº°·Î °üÂûµÈ 256ÁÖ°£ÀÇ È¿°ú °á°ú(ACR20/50/70, DAS28-CRP, CDAI)¿Í 268ÁÖ°£ÀÇ ´©Àû ¾ÈÀü¼º °á°ú°¡ º¸°íµÇ¾ú´Ù. ÇÑ ¿¬±¸±â°ü (16¸í)¿¡¼­ÀÇ È¿°ú µ¥ÀÌÅÍ´Â ÀÓ»ó°èȹ¼­ À§¹ÝÀ¸·Î Á¦¿ÜµÇ¾ú´Ù
 
°á°ú: 461¸íÀÌ ¹«ÀÛÀ§ ¹èÁ¤µÇ¾î, 459¸íÀÌ ½ÃÇè¾à¹°À» Åõ¿© ¹Þ¾Ò´Ù. 183¸í(40%)ÀÌ 252ÁÖ°£ Ä¡·á¸¦ °è¼ÓÇÏ¿´°í. 276¸íÀÌ Å»¶ôÇÏ¿´´Ù. (ÀÌ»ó¹ÝÀÀ: 86¸í. È¿°ú ºÎÁ·: 107¸í(23.3%), ÃßÀû ½ÇÆÐ: 9¸í, ±âŸ: 69¸í, »ç¸Á: 5¸í). 178¸íÀÌ 268ÁÖ µ¿¾È ¾ÈÀü¼º ÃßÀû°üÂûÀ» ¿Ï·áÇÏ¿´´Ù. 256ÁÖ±îÁö Æò°¡µÈ ȯÀÚµé Áß¿¡ 60.3%°¡ ACR 20¿¡, 42.3%°¡ ACR50¿¡, 21.7%°¡ ACR 70¿¡ µµ´ÞÇÏ¿´°í, 84.3%°¡ DAS28-CRP EULAR response¿¡ µµ´ÞÇÏ¿´´Ù. 29.0%°¡ DAS28-CRP <2.6¸¦ º¸¿´°í, 16.0%°¡ CDAI¡Â2.8À» º¸¿´´Ù. °¡Àå ÀϹÝÀûÀÎ ÀÌ»ó¹ÝÀÀÀº »ó±âµµ°¨¿°(27.1%), ºÎºñµ¿¿°(17.1%), ºñÀεο°(16.9%)À̾ú´Ù. 268ÁÖ°£ 431¸íÁß 151¸í(35%)ÀÌ Áß´ëÇÑ ÀÌ»ó¹ÝÀÀÀ» º¸¿´´Âµ¥, ÀÌ´Â ¿ë·®±ºº°·Î À¯»çÇÑ ºñÀ²·Î ³ªÅ¸³µ´Ù. Áß´ëÇÑ °¨¿°, ¾Ç¼ºÁ¾¾ç, »ç¸ÁÀÇ ºñÀ²Àº °¢°¢ 13.9%, 4.6%, 2.1%¿´´Ù. ȯÀÚµé Áß 12.3%¿¡¼­ 1°¡Áö ÀÌ»óÀÇ ÁÖ»çºÎÀ§¹ÝÀÀÀ» °æÇèÇÏ¿´´Ù. 388¸í Áß 31¸í(8.0%)¿¡¼­ antibody-to-golimumab¿¡ ¾ç¼ºÀ» º¸¿´´Ù.
 
°á·Ð: °ñ¸®¹«¸¿ÀÇ È¿°ú´Â Ä¡·á¸¦ °è¼ÓÇÑ ºÒÀÀ¼º ·ù¸¶Æ¼½º°üÀý¿° ȯÀڵ鿡¼­µµ 5³â°£ À¯ÁöµÇ¾ú´Ù.  °ñ¸®¹«¸¿ÀÇ Àå±â ¾ÈÀü¼ºÀº ´Ù¸¥ Ç×TNF¾ËÆÄ Á¦Á¦¿Í ºñ½ÁÇÏ¿´´Ù.
 
THU0352
GO-RAISE 5³â ÀÓ»ó °á°ú
 
°­Á÷¼º ôÃß¿° Ä¡·á¿¡ À־ °ñ¸®¹«¸¿ÀÇ Àå±â ¾ÈÀü¼º ¹× È¿´É: GO-RAISE ¿¬±¸ÀÇ 5³â °á°ú
A. Deodhar 1,*, J. Braun 2, R. Inman 3, D. van der Heijde 4, Y. Zhou 5, B. Hsu 5
1Oregon Health & Science Univ, Portland, United States, 2Rheumazentrum Ruhrgebiet/Ruhr-University Bochum, Herne, Germany, 3Univ of Toronto, Toronto, Canada, 4Leiden Univ Medical Center, Leiden, Netherlands, 5Janssen R&D, LLC, Spring House, United States
 
¹è°æ: °ñ¸®¹«¸¿Àº °­Á÷¼ºÃ´Ãß¿° ȯÀÚ¸¦ ´ë»óÀ¸·Î ÇÑ 2³â °£ÀÇ ¹«ÀÛÀ§¹èÁ¤, À§¾à ´ëÁ¶, 3»ó ÀÓ»ó ¿¬±¸ÀÎ GO-RAISE ¿¬±¸¿¡¼­ À¯ÀǼº ÀÖ°í Áö¼ÓÀûÀÎ ÀÓ»óÀû È¿´É°ú Çã¿ë °¡´ÉÇÑ ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» º¸¿´½À´Ï´Ù.
 
¸ñÀû: 5³â°£ °ñ¸®¹«¸¿ 50mg ±×¸®°í/¶Ç´Â 100mgÀ» Åõ¿© ¹ÞÀº °­Á÷¼º ôÃß¿° ȯÀÚ¿¡¼­ÀÇ °ñ¸®¹«¸¿ÀÇ ¾ÈÀü¼º/È¿´ÉÀ» Æò°¡ÇÑ´Ù.
¹æ¹ý: °­Á÷¼ºÃ´Ãß¿° ȯÀÚ 356¸íÀº ¹«ÀÛÀ§·Î À§¾à±º, °ñ¸®¹«¸¿ 50mg±º ¶Ç´Â °ñ¸®¹«¸¿ 100mg±º¿¡ ¹èÁ¤¹Þ¾Æ 4ÁÖ¸¶´Ù ÇÇÇÏÁÖ»ç·Î Åõ¿©µÇ¾ú½À´Ï´Ù. 16ÁÖÂ÷¿¡ ºÒÃæºÐÇÑ ¹ÝÀÀÀ» º¸À̴ ȯÀÚµéÀº ¸Í°Ë »óÅ·Πearly escape(EE)µÇ¾î ¿ë·® Á¶Á¤À» ÇÏ¿´½À´Ï´Ù(À§¾à¡æ°ñ¸®¹«¸¿ 50mg, °ñ¸®¹«¸¿50mg¡æ100mg). 24ÁÖÂ÷¿¡ ¿©ÀüÈ÷ À§¾àÀ» Åõ¿© ¹Þ°í ÀÖ´ø ȯÀÚµéÀº °ñ¸®¹«¸¿ 50mgÀ¸·Î ±³Â÷ Åõ¿© µÇ¾ú½À´Ï´Ù. ȯÀÚµéÀº 100ÁÖÂ÷±îÁö ÀÌÁß ¸Í°ËÀ¸·Î Åõ¿©¸¦ °è¼ÓÇÏ¿´½À´Ï´Ù. Àå±â ¿¬Àå ¿¬±¸´Â 104ÁÖÂ÷¿¡ °ñ¸®¹«¸¿À» Åõ¿© ¹ÞÀ½À¸·Î½á ½ÃÀ۵Ǿú½À´Ï´Ù. ȯÀÚµéÀº 5³â µ¿¾È 4ÁÖ ¸¶´Ù °ñ¸®¹«¸¿À» Åõ¿© ¹Þ¾Ò½À´Ï´Ù(¸¶Áö¸· Åõ¿©´Â 252ÁÖÂ÷). 104ÁÖÂ÷¿¡ ¸Í°ËÀÌ Á¾·á µÈ ÈÄ¿¡´Â ¿¬±¸ÀÚÀÇ ÆÇ´Ü ÇÏ¿¡ °ñ¸®¹«¸¿ 50mgÀ» Åõ¿© ¹Þ´Â ȯÀÚ¸¦ 100mgÀ¸·Î Áõ·® Åõ¿©Çϰųª, °ñ¸®¹«¸¿ 100mgÀ» Åõ¿© ¹Þ´Â ȯÀÚ´Â 50mgÀ¸·Î °¨·® Åõ¿©ÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù; ÇÔ²² Åõ¿©µÇ°í ÀÖ´ø DMARD, corticosteroid, NSAID ¾àÁ¦µµ Á¶ÀýµÉ ¼ö ÀÖ¾ú½À´Ï´Ù.
 
°á°ú: ¹«ÀÛÀ§ ¹èÁ¤µÈ 356¸íÀÇ È¯ÀÚ Áß 254¸í(71%)ÀÌ 252ÁÖ µ¿¾È Ä¡·á¸¦ À¯ÁöÇÏ¿´½À´Ï´Ù. 242¸íÀº 268ÁÖ°£ÀÇ ¾ÈÀü¼º ÃßÀûÁ¶»ç¸¦ ¿Ï·áÇÏ¿´½À´Ï´Ù. 101¸íÀº Ä¡·á¸¦ Áß´ÜÇÏ¿´½À´Ï´Ù(ÀÌ»ó¹ÝÀÀÀ¸·Î ÀÎÇØ 33¸í[9.3%], È¿°ú ºÎÁ·À¸·Î 35¸í[9.8%], ÃßÀû Á¶»ç ½ÇÆзΠ11¸í[3.1%] ±âŸ ÀÌÀ¯·Î 22¸í[6.2%]); 1¸íÀº Ä¡·á¸¦ ¹ÞÁö ¾Ê¾Ò½À´Ï´Ù. °­Á÷¼ºÃ´Ãß¿°°ú ¿¬°üµÈ Áõ»ó/ÁõÈÄÀÇ °¨¼Ò, ½ÅüÀû ±â´É ¹× ¿îµ¿ ¹üÀ§ °³¼±ÀÌ 14ÁÖÂ÷¿¡ °üÂûµÇ¾úÀ¸¸ç(1Â÷ °á°úº¯¼ö Æò°¡ ½ÃÁ¡; ÀÌÀü ¿¬±¸¿¡¼­ º¸°íµÊ) 5³â µ¿¾È À¯ÁöµÇ¾ú½À´Ï´Ù(Ç¥ Âü°í). Áß´ëÇÑ ÀÌ»ó¹ÝÀÀÀº °ñ¸®¹«¸¿ 50mg±º¿¡¼­ 17.1%, 100mg±º¿¡¼­ 24.7%, ±×¸®°í Àüü °ñ¸®¹«¸¿ Åõ¿©±º¿¡¼­ 22.0%·Î º¸°íµÇ¾ú½À´Ï´Ù. 1¸íÀÌ »ç¸Á(°ñ¸®¹«¸¿ 50mg±º, ¿¬±¸¿¡ Âü¿©ÇÑ Áö 3³â ÈÄ¿¡ B ¼¼Æ÷ ¸²ÇÁÁ¾ÀÌ ¹ßº´, ÃéÀå¾ÏÀ¸·Î À̾îÁü)ÇÏ¿´½À´Ï´Ù
 
°á·Ð: È°¼º °­Á÷¼º ôÃß¿° ȯÀÚ¿¡°Ô ÀÖ¾î 4ÁÖ ¸¶´Ù ÇÇÇÏ·Î °ñ¸®¹«¸¿ 50mg°ú 100mgÀ» Åõ¿©ÇÑ °á°ú, °­Á÷¼º ôÃß¿°ÀÇ Áõ»ó/ÁõÈÄ, ½ÅüÀû ±â´É, ¿îµ¿ ¹üÀ§°¡ °³¼±µÇ¾úÀ¸¸ç, ¸¸Á·½º·¯¿î ¾ÈÀü¼º ÇÁ·ÎÆÄÀÏÀ» º¸¿´À¸¸ç, ÀÌ °á°ú´Â 160ÁÖÂ÷±îÁö ¾Õ¼­ º¸°íµÈ°ñ¸®¹«¸¿ÀÇ °á°ú ¹× ´Ù¸¥ Ç× TNF »ý¹°ÇÐÀûÁ¦Á¦µé°ú µ¿µîÇÏ¿´½À´Ï´Ù. °ñ¸®¹«¸¿ÀÇ µÎ ¿ë·® °£¿¡´Â Â÷ÀÌ°¡ ¾ø¾ú½À´Ï´Ù.
 
Disclosure of Interest: A. Deodhar Grant/research support from: Janssen R&D, LLC, J. Braun Grant/research support from: Janssen R&D, LLC, R. Inman Grant/research support from: Janssen R&D, LLC, D. van der Heijde Grant/research support from: Janssen R&D, LLC, Y. Zhou Shareholder of: Johnson & Johnson, Employee of: Janssen R&D, LLC, B. Hsu Shareholder of: Johnson & Johnson, Employee of: Janssen R&D, LLC
 
SAT0270
GO-REVEAL 5³â ÀÓ»ó °á°ú
È°¼º °Ç¼±¼º °üÀý¿°¿¡ ÀÖ¾î °ñ¸®¹«¸¿ÀÇ 5³â °£ÀÇ ¾ÈÀü¼º, È¿´É, ¹æ»ç¼±ÇÐÀû °á°ú: ¹«ÀÛÀ§¹èÁ¤, À§¾à´ëÁ¶ GO-REVEAL ¿¬±¸ÀÇ Àå±â ¿¬Àå ¿¬±¸ °á°ú
 
A. Kavanaugh 1,*, D. van der Heijde 2, I. McInnes 3, P. Mease 4, G. G. Krueger 5, D. Gladman 6, Y. Zhou 7, J. D. Lu 7, Z. Xu 7, L. Noonan 7, A. Beutler 7
 
1U of California, San Diego, La Jolla, United States, 2Leiden U Med Ctr, Leiden, Netherlands, 3U of Glasgow, Glasgow, United Kingdom, 4Swedish Med Ctr and U of Washington, Seattle, 5U of Utah, SLC, United States, 6U of Toronto, Toronto, Canada, 7Janssen R&D, LLC, Spring House, United States
 
¸ñÀû: GO-REVEAL ¿¬±¸ÀÇ Àå±â ¿¬Àå ¿¬±¸¸¦ ÅëÇØ °ñ¸®¹«¸¿À¸·Î Ä¡·á ¹ÞÀº ȯÀڵ鿡¼­ÀÇ ¾ÈÀü¼º, È¿´É, ¹æ»ç¼±ÇÐÀû ÁøÇà¿¡ ´ëÇÑ °á°ú°¡ º¸°íÇÑ´Ù.
 
¹æ¹ý: °Ç¼º¼± °üÀý¿°(Àû¾îµµ ¾ÐÅë °üÀý, ºÎÁ¾ °üÀýÀÇ ¼ö°¡ °¢ 3°³ ÀÌ»ó) ȯÀÚµé 405¸íÀº À§¾à±º(±×·ì1, 113¸í), °ñ¸®¹«¸¿50mg±º(±×·ì2, 146¸í), ¶Ç´Â °ñ¸®¹«¸¿100mg±º(±×·ì3, 146¸í)À¸·Î ¹«ÀÛÀ§ ¹èÁ¤µÇ¾î 20ÁÖ°£ ¸Å 4ÁÖ¸¶´Ù ÇÇÇÏ·Î ½ÃÇè¾àÀ» Åõ¿©¸¦ ¹Þ¾Ò½À´Ï´Ù. ±âÃÊÆò°¡½ÃÁ¡¿¡¼­ Åõ¿© ¹Þ°í ÀÖ´ø MTX´Â Çã¿ëµÇ¾úÀ¸³ª ¹Ýµå½Ã º´¿ëÇØ¾ß ÇÏ´Â °ÍÀº ¾Æ´Ï¾ú½À´Ï´Ù. 16ÁÖÂ÷¿¡ °üÀýÀÇ ¾ÐÅë°ú ºÎÁ¾ÀÌ 10% ¹Ì¸¸À¸·Î °³¼±µÈ ȯÀÚµéÀº ±¸Á¦ Ä¡·á¸¦ ¹ÞÀ» ¼ö ÀÖ¾ú½À´Ï´Ù. 24ÁÖ ÀÌÈÄ¿¡´Â ¸ðµç ȯÀÚµéÀÌ °ñ¸®¹«¸¿À» Åõ¿© ¹Þ¾Ò½À´Ï´Ù. 52ÁÖ ÀÌÈÄ È¯ÀÚµéÀº ¿¬±¸ÀÚÀÇ ÆÇ´Ü¿¡ µû¶ó °ñ¸®¹«¸¿ ¿ë·®À» Á¶Á¤ÇÒ ¼ö ÀÖ¾ú½À´Ï´Ù. °ñ¸®¹«¸¿ÀÇ ¸¶Áö¸· Åõ¿©´Â 252ÁÖÂ÷¿¡ ÀÌ·ç¾îÁ³½À´Ï´Ù; È¿´ÉÀº 256ÁÖÂ÷¿¡ ACR ¹ÝÀÀ ±âÁØ, DAS28-CRP, PASI, HAQ, °ñºÎÂøºÎÀ§¿°/°¡¶ô¿° Æò°¡, NAPSI Á¡¼ö ¹× PsA-modified Sharp/van der Heijde score(SHS)¸¦ ÅëÇØ randomized group&completer ºÐ¼®À¸·Î Æò°¡ÇÏ¿´½À´Ï´Ù. ¾ÈÀü¼º Æò°¡´Â 5³â°£ ÇÑ ¹øÀÌ¶óµµ °ñ¸®¹«¸¿À» Åõ¿© ¹ÞÀº ¸ðµç ȯÀÚ¸¦ Æ÷ÇÔÇÏ¿´½À´Ï´Ù.
 
°á°ú: ¹«ÀÛÀ§ ¹èÁ¤µÈ 405¸íÀÇ È¯ÀÚ Áß 335¸íÀÌ 104ÁÖ µ¿¾È, 279¸í(69%)Àº 252ÁÖ µ¿¾È °ñ¸®¹«¸¿ÀÇ Åõ¿©¸¦ À¯ÁöÇÏ¿´½À´Ï´Ù. ±×·ì2 ȯÀÚÀÇ 29%´Â °ñ¸®¹«¸¿ 100mgÀ¸·Î Áõ·® Åõ¿©ÇÏ¿´½À´Ï´Ù; ±×·ì3 ȯÀÚÀÇ 25%´Â 100mg¿¡¼­ 50mgÀ¸·Î °¨·® Åõ¿©ÇÏ¿´½À´Ï´Ù. 104ÁÖÂ÷±îÁö ¿¬±¸¸¦ Áö¼ÓÇÑ È¯ÀÚµéÀÇ ±âÃÊÆò°¡½ÃÁ¡¿¡¼­ÀÇ °³¿ä¿Í 256ÁÖÂ÷¿¡¼­ÀÇ È¿´ÉÀº Ç¥¿¡ ³ªÅ¸³ª ÀÖ½À´Ï´Ù. ACR°ú PASI ¹ÝÀÀÀº MTX¸¦ ÇÔ²² Åõ¿© ¹ÞÀº ȯÀÚ¿Í ±×·¸Áö ¾ÊÀº ȯÀÚ¿¡¼­ À¯»çÇÏ¿´½À´Ï´Ù; ±âÃÊÆò°¡½ÃÁ¡¿¡¼­ÀÇ SHS Á¡¼öÀÇ º¯È­´Â °ñ¸®¹«¸¿ ´Üµ¶ Åõ¿©±º°ú ºñ±³ÇÏ¿´À» ¶§ °ñ¸®¹«¸¿°ú MTXÀÇ º´¿ë Åõ¿©±º¿¡¼­ °¡Àå Àû¾úÀ¸¸ç ¼öÄ¡»óÀ¸·Îµµ ´õ Àû¾ú½À´Ï´Ù. °ñ¸®¹«¸¿ Åõ¿© ȯÀÚÀÇ 88%, 21%°¡ °¢°¢ ÀÌ»ó¹ÝÀÀ, Áß´ëÇÑ ÀÌ»ó¹ÝÀÀÀ» °æÇèÇÏ¿´½À´Ï´Ù. 12%ÀÇ È¯ÀÚ°¡ ÀÌ»ó¹ÝÀÀ ¶§¹®¿¡ °ñ¸®¹«¸¿ÀÇ Åõ¿©¸¦ Áß´ÜÇÏ¿´°í, 5%, 4%ÀÇ È¯ÀÚ°¡ °¢°¢ ¾Ç¼ºÁ¾¾ç(NMSC Æ÷ÇÔ), Áß´ëÇÑ °¨¿°À» °æÇèÇÏ¿´½À´Ï´Ù. °ñ¸®¹«¸¿¿¡ ´ëÇÑ Ç×ü´Â 6%ÀÇ È¯ÀÚ¿¡°Ô¼­ º¸°íµÇ¾ú½À´Ï´Ù.
 
°á·Ð: 5³â°£ °ñ¸®¹«¸¿ Ä¡·á¸¦ Áß´ÜÇÑ È¯ÀÚÀÇ ºñÀ²Àº ³·¾Ò½À´Ï´Ù. °ñ¸®¹«¸¿ÀÇ Åõ¿©·Î °Ç¼±¼º °üÀý¿°ÀÇ °üÀý¼º ¹× ÇǺΠÆò°¡ ¿ä¼Ò¿¡¼­ ÀÓ»óÀûÀ¸·Î ÀÇ¹Ì ÀÖ´Â ¹ÝÀÀÀÌ Àå±â°£ À¯ÁöµÇ¾úÀ¸¸ç, ½ÅüÀû ±â´ÉÀÌ °³¼±µÇ¾ú°í, ¹æ»ç¼±ÇÐÀû ÁøÇàÀÌ ¾ïÁ¦µÇ¾ú½À´Ï´Ù. °ñ¸®¹«¸¿ÀÇ µÎ ¿ë·®À» ¸Å 4ÁÖ¸¶´Ù Åõ¿©ÇÑ °á°ú Àå±â ¾ÈÀü¼º ¹× È¿´É¿¡¼­ ¸í¹éÇÑ Â÷À̸¦ º¸ÀÌÁö ¾Ê¾ÒÀ¸³ª, ¹«ÀÛÀ§ ±×·ì °£ÀÇ Ä¡·á º¯°æÀÌ Çã¿ëµÇ¾ú¾ú±â ¶§¹®¿¡ ÀÚ·á Çؼ®¿¡ ÀÖ¾î ÇÑ°è°¡ ÀÖ½À´Ï´Ù
 
Disclosure of Interest: A. Kavanaugh Grant/research support from: Janssen Research and Development, LLC, D. van der Heijde Grant/research support from: Janssen Research and Development, LLC, I. McInnes Grant/research support from: Janssen Research and Development, LLC, P. Mease Grant/research support from: Janssen Research and Development, LLC, G. G. Krueger Grant/research support from: Janssen Research and Development, LLC, D. Gladman Grant/research support from: Janssen Research and Development, LLC, Y. Zhou Employee of: Janssen Research and Development, LLC, J. D. Lu Employee of: Janssen Research and Development, LLC, Z. Xu Employee of: Janssen Research and Development, LLC, L. Noonan Employee of: Janssen Research and Development, LLC, A. Beutler Employee of: Janssen Research
and Development, LLC
 
THU0513
°ñ¸®¹«¸¿ 3»ó Àå±âÀÓ»óµé¿¡¼­ÀÇ »îÀÇ Áú µîÀÇ È¿°úº¸°í
°ñ¸®¹«¸¿À» Åõ¿© ¹ÞÀº ·ù¸¶Æ¼½º°üÀý¿°, °Ç¼±¼º °üÀý¿°, °­Á÷¼º ôÃß¿° ȯÀڵ鿡¼­ÀÇ »îÀÇ Áú, »ý»ê¼º, Ãë¾÷´É·ÂÀÇ °³¼± ¹× ÀÇ·á ÀÚ¿ø ÀÌ¿ë °¨¼ÒÀÇ Áö¼Ó: 5³â °á°ú
 
C. Han 1,*, A. Kavanaugh 2, M. C. Genovese 3, A. Deodhar 4, B. Hsu 5, E. Hsia 5
1Janssen Global Services, LLC, Malvern, 2U of California-San Diego, La Jolla, 3Stanford U,
Palo Alto, 4Oregon Health and Science U, Portland, 5Janssen R & D, LLC, Spring House,
United States
 
¸ñÀû: 5³â°£ °ñ¸®¹«¸¿À» Åõ¿© ¹ÞÀº ·ù¸¶Æ¼½º°üÀý¿°, °Ç¼±¼º °üÀý¿°, °­Á÷¼º ôÃß¿° ȯÀڵ鿡¼­ÀÇ °Ç°­ °ü·Ã »îÀÇ Áú, »ý»ê¼º°ú Ãë¾÷´É·Â¿¡ ¹ÌÄ¡´Â Áúº´ÀÇ ¿µÇâ°ú ÀÇ·á ÀÚ¿ø ÀÌ¿ëÀÇ º¯È­¸¦ ±âÃÊ Æò°¡ ½ÃÁ¡ ´ëºñ ¿ä¾à
 
¹æ¹ý: MTX Åõ¿©¿¡µµ È°¼º ·ù¸¶Æ¼½º°üÀý¿°(GO-FORWARD), È°¼º °Ç¼±¼º°üÀý¿°(GO-REVEAL), È°¼º °­Á÷¼º ôÃß¿°(GO-RAISE) ȯÀÚµéÀ» À§¾à ¶Ç´Â °ñ¸®¹«¸¿(50mg ¶Ç´Â 100mgÀ» ¸Å4ÁÖ¸¶´Ù Åõ¿©)±ºÀ¸·Î ¹«ÀÛÀ§¹èÁ¤ÇÏ¿´½À´Ï´Ù GO-FORWARD ¿¬±¸¿¡¼­´Â MTX¿ÍÀÇ º´¿ë Åõ¿©µµ Æ÷ÇԵǾú½À´Ï´Ù(GO-FORWARD¿¡¼­ GLM ´Üµ¶ Åõ¿© °á°ú´Â ÀÌ ºÐ¼®¿¡ Æ÷ÇÔµÇÁö ¾Ê¾Ò´Ù.). À§¾à±ºÀ¸·Î ¹«ÀÛÀ§ ¹èÁ¤ µÇ¾ú´ø ȯÀÚ´Â 24ÁÖÂ÷¿¡ °ñ¸®¹«¸¿À¸·Î º¯È¯ Åõ¿©ÇÏ¿©, 256ÁÖ±îÁö ÃßÀû Á¶»ç ÇÏ¿´½À´Ï´Ù. HRQOLÀº SF-36À» ÀÌ¿ëÇÏ¿©,, »ý»ê¼º¿¡ ´ëÇÑ Áúº´ÀÇ ¿µÇâÀº VAS(0=¿µÇâ ¾øÀ½, 10=¸Å¿ì ¿µÇâÀ» ³¢Ä§)¸¦ ÀÌ¿ëÇÏ¿© Æò°¡µÇ¾ú½À´Ï´Ù. Ãë¾÷´É·ÂÀº ÇöÀç Á÷Àå¿¡¼­ È°µ¿ÀûÀ¸·Î ÀÏÇÏ°í Àְųª Á÷¾÷ÀÌ ÀÖÀ» ¶§, ÀÏÀ» ÇÒ ¼ö Àִ°¡¸¦ ±âÁØÀ¸·Î Æò°¡ ÇÏ¿´½À´Ï´Ù. ÀÇ·á ÀÚ¿ø ÀÌ¿ëÀº Áö³­ 4ÁÖ°£ÀÇ ¿Ü·¡ Áø·á Ƚ¼ö, Áö³­ 3°³¿ù µ¿¾ÈÀÇ ÀÀ±Þ½Ç ¹æ¹® Ƚ¼ö, Áö°£ 12°³¿ù µ¿¾ÈÀÇ ÀÔ¿ø Ƚ¼ö¸¦ Æ÷ÇÔÇÏ¿´½À´Ï´Ù. SF-36ÀÇ ½ÅüÀû ¿ä¼Ò ¿ä¾à(PCS) ¹× Á¤½ÅÀû ¿ä¼Ò ¿ä¾à(MCS), »ý»ê¼º, Ãë¾÷´É·Â, ÀÇ·á ÀÚ¿ø ÀÌ¿ëÀÇ ±âÃÊ Æò°¡ ½ÃÁ¡ ´ëºñ 256ÁÖ µ¿¾ÈÀÇ º¯È­¸¦ Á¤¸®ÇÏ¿´½À´Ï´Ù.
 
°á°ú: ±âÃÊ Æò°¡ ½ÃÁ¡¿¡ Àüü °ñ¸®¹«¸¿ ±º(RA, PsA, AS)ÀÇ SF-36 PCS(30.19, 32.91, and 30.00)¿Í MCS(43.65, 45.19, and 44.03)ÀÇ Æò±Õ°ªÀº ÀÏ¹Ý ¹Ì±¹Àα¸¿¡¼­º¸´Ù ³·¾Æ »îÀÇ ÁúÀÌ ³·Àº °ÍÀ» º¸¿´½À´Ï´Ù. ±âÃÊ Æò°¡ ½ÃÁ¡¿¡¼­ ÀºÅð Àü ½Ç¾÷ »óÅÂÀÎ RA, PsA, AS ȯÀÚµéÀº °¢°¢ 13.7%, 12.1%, 14.1% ¿´½À´Ï´Ù. 24ÁÖÂ÷¿¡ °ñ¸®¹«¸¿À» Åõ¿© ¹ÞÀº RA, PsA, AS ȯÀÚµéÀº Æò±Õ SF-36 PCS(7.65, 7.83, and 9.36, p<0.001),
MCS (3.07, 3.84, and 4.01, p <0.05) Á¡¼ö¿¡¼­ Åë°èÀûÀ¸·Î À¯ÀÇÇÏ°Ô °³¼±µÈ °á°ú¸¦ º¸¿´°í, ±âÃÊ Æò°¡ ½ÃÁ¡ ´ëºñ »ý»ê¼º¿¡ ¹ÌÄ¡´Â Áúº´ÀÇ ¿µÇâµµ À§¾à´ëºñ Àüü °ñ¸®¹«¸¿ ±º¿¡¼­ À¯ÀÇÇÏ°Ô ´õ Å« °¨¼Ò¸¦ º¸¿´½À´Ï´Ù(.1.987, .2.242, .2.805, all p<0.001). °ñ¸®¹«¸¿À» Åõ¿© ¹ÞÀº RA, PsA, AS ȯÀڵ鿡¼­ 256ÁÖÂ÷¿¡µµ SF-36 PCS, MSCÀÇ Áö¼ÓÀûÀÎ °³¼±À» º¸¿´À¸¸ç (±âÃÊ Æò°¡ ½ÃÁ¡ ´ëºñ Æò±Õ º¯È­: PCS 9.3, 9.8, and 13.0 and MCS 4.5, 4.7, and 5.1, respectively), Áúº´ÀÌ »ý»ê¼º¿¡ ¿µÇâÀ» ÁÖ´Â Á¤µµ¿¡ °üÇÑ Æò±Õ°ª º¯È­´Â RA, PsA, AS °¢°¢ -2.71, -3.0, -3.9 ¿´½À´Ï´Ù. ±×¸®°í ±âÃÊ Æò°¡ ½ÃÁ¡¿¡¼­ Ãë¾÷ °¡´ÉÇÑ RA, PsA, AS ȯÀÚµéÀº ¸ðµÎ 95% ÀÌ»ó Áö¼ÓµÇ¾ú°í, ±âÃÊ Æò°¡ ½ÃÁ¡¿¡ Ãë¾÷ºÒ°¡´É(unemployable) »óÅ¿´´ø ȯÀÚµéÀº Á» ´õ Ãë¾÷À» ÇÒ ¼ö ÀÖ´Â »óÅ°¡ µÇ¾ú½À´Ï´Ù. (RA 33.3%, PsA 64.3%, and AS 76.5%) ¿Ü·¡ Áø·á´Â ÁÙ¾îµç °Í(RA .84%, PsA .89%, and AS .88%)À¸·Î À¸·Î ³ªÅ¸³µ°í, ÀÔ¿øÀ̳ª ÀÀ±Þ½Ç ¹æ¹®ÀÌ µå¹°¾úÁö¸¸, ÀÔ¿ø ¹× ÀÀ±Þ½Ç ¹æ¹® Ƚ¼ö, ÀÔ¿ø Àϼö ¶ÇÇÑ °¨¼Ò¸¦ º¸¿´½À´Ï´Ù. ±âÃÊ Æò°¡ ½ÃÁ¡¿¡¼­ À§¾à±ºÀ¸·Î ¹«ÀÛÀ§ ¹èÁ¤µÇ¾ú´Ù°¡ °ñ¸®¹«¸¿À¸·Î º¯È¯ Åõ¿©¹ÞÀº ȯÀÚµé ¿ª½Ã ½Ã°£ÀÌ Áö³²¿¡ µû¶ó óÀ½ºÎÅÍ °ñ¸®¹«¸¿À» Åõ¿© ¹ÞÀº ȯÀÚµé ºñ½ÁÇÑ °á°ú¸¦ º¸¿´½À´Ï´Ù.
 
°á·Ð: °ñ¸®¹«¸¿À» Åõ¿© ¹ÞÀº ȯÀÚµéÀº °Ç°­ °ü·Ã »îÀÇ ÁúÀÇ °³¼±, »ý»ê¼º¿¡ ´ëÇÑ Áúº´ÀÇ ¿µÇâ °¨¼Ò, °³¼±µÈ Ãë¾÷´É·Â, ÀÇ·á ÀÚ¿ø ÀÌ¿ë °¨¼Ò°¡ 5³â°£ Áö¼ÓµÊÀ» º¸¿´½À´Ï´Ù.
 
Disclosure of Interest: None Declared
 
FRI0174
·ù¸¶Æ¼½º°üÀý¿° Ä¡·á¿¡¼­ »ý¹°ÇÐÀû Á¦Á¦ÀÇ ÇÇÇÏ ÁÖ»ç½ÃÀÇ ÅëÁõ Æò°¡
 
M. Sato 1,*, M. Takemura 2, R. Shinohe 3
1Orthopaedic Suregery, 2Clinical Informative Medicine, Gifu University Hospital,
3Orthopaedic Surgery, Nishimino Welfare Hospital, Gifu, Japan
 
¹è°æ: »ý¹°ÇÐÀû Á¦Á¦´Â ·ù¸¶Æ¼½º°üÀý¿°ÀÇ Ä¡·á¿¡ À־ ±ØÀûÀÎ º¯È­¸¦ °¡Á®¿Ô´Ù. ÃÖ±Ù ¸î ³â°£, ¸î¸î »ý¹°ÇÐÀû Á¦Á¦°¡ »õ·Î Çã°¡¸¦ ¹Þ¾Ò°í, ±× Áß Àý¹Ý Á¤µµ°¡ ÇÇÇÏÁÖ»çÁ¦·Î Ãâ½Ã µÇ¾ú´Ù. ÇÏÁö¸¸ ÇÇÇÏÁÖ»ç·Î ÀÎÇÑ ÅëÁõÀº ÀϺΠȯÀÚ¿¡°Ô¼­ ¹®Á¦°¡ µÉ ¼öµµ ÀÖ´Ù.
 
¸ñÀû: ÇÇÇÏÁÖ»ç·Î »ý¹°ÇÐÀû Á¦Á¦¸¦ Åõ¿©Çϴ ȯÀÚ¿¡¼­ ÀÌ·Î ÀÎÇØ ¹ß»ýÇÏ´Â ÅëÁõÀÇ ÁßÁõµµ Æò°¡.
 
¹æ¹ý: ÇÇÇÏÁÖ»ç ½Ã ¹ß»ýÇÏ´Â ÅëÁõÀº VAS¸¦ ÅëÇØ Æò°¡ µÇ¾ú´Ù. VAS´Â °¢°¢ÀÇ ¼Ò °£°Ý¸¶´Ù ÅëÁõÀÇ Á¤µµ°¡ ¹¦»çµÈ 10cmÀÇ ÆòÇàÇÑ ¼±ÀÌ´Ù. ȯÀÚµéÀº ÇÇÇÏÁÖ»ç ½Ã ´À²¸Áö´Â ÅëÁõ Á¤µµ¸¦ 0Á¡(ÅëÁõ ¾øÀ½)¿¡¼­ 100Á¡(°¡Àå ÂüÀ» ¼ö ¾ø´Â ÅëÁõ)±îÁö Ç¥½ÃµÈ Á¡¼ö·Î Ç¥±âÇÑ´Ù. ȯÀÚµéÀº °¢ÀÚ ¸Â°í ÀÖ´Â ÇÇÇÏ ÁÖ»çÀÇ °¡Àå ÃÖ´ë ÅëÁõÀ» ±â·ÏÇÏ¿´´Ù. Etanercept (ETN), adalimumab (ADA), and golimumab (GOL) °¢°¢Àº ÀÌÀü ȤÀº ÇöÀç »óȲ¿¡¼­ ȯÀÚµéÀÌ ¼±Åà °¡´É ÇÏ°Ô ÇÏ¿´´Ù. ´ëÁ¶¾àÀ¸·Î´Â µ¶°¨ ¹é½Å(IV, influenza vaccination)ÀÌ »ç¿ëµÇ¾ú´Ù.
 
°á°ú: ÃÑ 123¸íÀÇ ·ù¸¶Æ¼½º°üÀý¿° ȯÀÚ (Æò±Õ ³ªÀÌ 59¼¼, ¹üÀ§ 30~84¼¼)°¡ ÀÌ ¿¬±¸¿¡ Âü¿© ÇÏ¿´´Ù. ¿©¼ºÀº 104¸íÀ¸·Î 84.6%¿´´Ù. IV, ETN, ADA, GOLÀÇ Åõ¿©¿¡ ´ëÇÑ VAS Á¡¼ö¸¦ Æò°¡ÇÑ È¯ÀÚ´Â ¼ø¼­´ë·Î °¢°¢ 123, 70, 60, 17¸í À̾ú´Ù. VAS Á¡¼ö´Â °¢°¢ (median, IQR) ´ÙÀ½°ú °°¾Ò´Ù. (IV, 26, 15-46; ETN, 41, 22.5-57; ADA, 59, 30-82.7; and GOL, 35, 27-41.) VAS ºñÀ²(°¢ »ý¹°ÇÐÀû Á¦Á¦ÀÇ VAS Á¡¼ö/ IVÀÇ VAS Á¡¼ö)¸¦ Àû¿ëÇÑ ÈÄ, °¢°¢ÀÇ VAS ratio´Â(median, IQR) ´ÙÀ½°ú °°´Ù: ETN/IV, 1.140, 0.736-2.189; ADA/IV, 1.627, 0.973-3.898; and GOL/IV, 0.949, 0.800-1.125. GOLÀÇ VAS Á¡¼ö´Â µ¶°¨ ¹é½Å°ú °ÅÀÇ °°¾Ò´Ù. ÇÇÇÏÁÖ»ç ½Ã GOLÀº »ó±â »ý¹°ÇÐÀû Á¦Á¦ Áß °¡Àå ÅëÁõÀÌ ´ú ÇÑ °ÍÀ¸·Î º¸ÀδÙ. (GOL vs. ADA, p = 0.0052 and ETN vs. ADA, p = 0.0060) ¶ÇÇÑ ´ëºÎºÐÀÇ È¯ÀÚµéÀº Áֻ縦 Â´Â ¼ø°£ÀÌ ¾Æ´Ï¶ó, »ý¹°ÇÐÀû Á¦Á¦°¡ Åõ¿©µÇ´Â ¼ø°£ÀÌ °¡Àå ºÒÆíÇÏ´Ù°í ÀÀ´äÇß´Ù.
 
°á·Ð: ÇÇÇÏÁÖ»ç·Î ÀÎÇÑ ÅëÁõ¿¡ ´ëÇÑ ÀÌ È¯ÀÚ-ÁÖµµÇü Æò°¡´Â °ñ¸®¹«¸¿ÀÇ Åõ¿©°¡ ´Ù¸¥ »ý¹°ÇÐÀû Á¦Á¦µé ´ëºñ ÀûÀº ÅëÁõÀ» À¯¹ßÇÑ´Ù´Â °ÍÀ» º¸¿©ÁØ´Ù. ºñ·Ï ÁÖ»ç¿Í °ü·ÃÇÑ ÅëÁõÀÇ Æò°¡´Â ȯÀÚ¸¶´Ù ´Ù¸¦ ¼ö ÀÖÁö¸¸, ȯÀÚµéÀÇ ÆíÀǼºÀ» Çâ»ó½ÃÅ°°í ·ù¸¶Æ¼½º°üÀý¿° Ä¡·á¿¡ ´ëÇÑ ¼øÀÀµµ¸¦ ¿Ã¸®±â À§Çؼ­´Â ´õ¿í ÆíÇÑ ÇÇÇÏÁÖ»çÁ¦°¡ ÇÊ¿äÇÏ´Ù.
 
Disclosure of Interest: None Declared
 
*º» ÀÚ·á´Â À¯·´·ù¸¶Æ¼½º ÇÐȸ¿¡¼­ ¹ßÇ¥µÈ ½ÉÆÛ´ÏÀÇ ÁÖ¿ä Àӻ󿬱¸°á°ú¸¦ ¿ä¾àÇÑ ÀÚ·á·Î ¹«´Ü¹èÆ÷¸¦ ±ÝÁöÇÕ´Ï´Ù*
[ ÇÏÁ¤È¯ ±âÀÚ news@medicalilbo.com ]
ÇÏÁ¤È¯ ±âÀÚ ±âÀÚÀÇ ´Ù¸¥ ±â»ç º¸±â
±â»çÁ¦º¸ ¹× º¸µµÀÚ·á news@medicalilbo.com
¢Æ¢Æ ÀÇ·áÀϺ¸ ¢Æ¢Æ(www.medicalilbo.com) - copyright ¨Ï ¢Æ¢Æ ÀÇ·áÀϺ¸ ¢Æ¢Æ. ¹«´ÜÀüÀç & Àç¹èÆ÷ ±ÝÁö
´ñ±Û´Þ±â
  • ¸¹À̺»±â»ç
  • È­Á¦ÀÇ ´º½º

È­Á¦ÀÇ Æ÷Åä

È­Á¦ÀÇ Æ÷Åä´õº¸±â

    È­Á¦Àǵ¿¿µ»ó

    È­Á¦ÀÇ µ¿¿µ»ó
    • ȸ»ç¼Ò°³
    • ±¤°í¾È³»
    • Á¦ÈÞ·±¤°í¹®ÀÇ
    • ±â»çÁ¦º¸
    • Á¤±â±¸µ¶½Åû
    • °í°´¼¾ÅÍ
    • ÀúÀÛ±ÇÁ¤Ã¥
    • ȸ¿ø¾à°ü
    • °³ÀÎÁ¤º¸Ãë±Þ¹æħ
    • À̸ÞÀÏÁÖ¼Ò¹«´Ü¼öÁý°ÅºÎ
    • RSS
    • ÀÇ·áÀϺ¸ www.medicalilbo.com | ¼³¸³ÀÏ : 2009³â 9¿ù 7ÀÏ | ¥Ø 06653 ¼­¿ï½Ã ¼­Ãʱ¸ ¼­Ãʵ¿ 1589-14 ½Å¼º¿ÀÇǽºÅÚ Bµ¿ 407È£
      »ç¾÷ÀÚµî·Ï¹øÈ£ : 105-07-38362 | µî·Ï¹øÈ£ : ¼­¿ï½Ã ´Ù 09845
      ÀüÈ­ : 02) 333-3739, 363-3730 ±¤°í¹®ÀÇ : 02) 333-3739 | Æѽº 02) 363-3730 |  news@medicalilbo.com
      Copyright ¨Ï 2009 medicalilbo.com All right reserved.
      ¢Æ¢Æ ÀÇ·áÀϺ¸ ¢Æ¢ÆÀÇ ¸ðµç ÄÜÅÙÃ÷(±â»ç)´Â ÀúÀ۱ǹýÀÇ º¸È£¸¦ ¹Þ½À´Ï´Ù. ¹«´Ü ÀüÀç·º¹»ç·¹èÆ÷ µîÀ» ±ÝÇÕ´Ï´Ù.